Wells Timothy Steven, Sato Paul A, Smith Tyler Clain, Wang Linda Zhenling, Reed Robert John, Ryan Margaret Angela Kappel
Department of Defense Center for Deployment Health Research, Naval Health Research Center, San Diego, California, USA.
Hum Vaccin. 2006 Mar-Apr;2(2):54-9. doi: 10.4161/hv.2.2.2589. Epub 2006 Mar 13.
Safety concerns have confronted the Department of Defense Anthrax Vaccine Immunization Program since inception in 1998. To determine if anthrax vaccination was associated with an increased risk of hospitalization, a historical cohort study utilizing pre- and post-anthrax-vaccination hospitalizations was undertaken and analyzed with Cox proportional hazards models. The study population consisted of 170,723 active duty US service members who were anthrax-vaccinated and deployed during the time period January 1, 1998 to December 31, 2001. Study outcomes included hospitalizations due to any-cause, 14 broad International Classification of Diseases diagnostic categories, autoimmune organ specific and organ non-specific hospitalizations, and asthma. After adjustment, anthrax vaccination was associated with significantly fewer hospitalizations for any-cause, diseases of the blood and blood forming organs, and diseases of the respiratory system. Comparing anthrax post-vaccination hospitalization experience with the pre-vaccination period resulted in no significant increased hazard for any of the hospitalization outcomes studied. Although there was no apparent increase in risk of morbidity in this study population, the relationship between anthrax vaccine and deployment on health outcomes among US service members needs further study.
自1998年启动以来,美国国防部炭疽疫苗免疫计划一直面临安全问题。为了确定接种炭疽疫苗是否会增加住院风险,开展了一项历史性队列研究,利用接种炭疽疫苗前后的住院情况,并采用Cox比例风险模型进行分析。研究人群包括1998年1月1日至2001年12月31日期间接种炭疽疫苗并被部署的170,723名美国现役军人。研究结果包括因任何原因住院、14个广泛的国际疾病分类诊断类别、自身免疫性器官特异性和器官非特异性住院以及哮喘。调整后,接种炭疽疫苗与因任何原因、血液及造血器官疾病和呼吸系统疾病住院的人数显著减少有关。将接种炭疽疫苗后的住院经历与接种前时期进行比较,在所研究的任何住院结果中,均未发现风险显著增加。尽管该研究人群中发病率没有明显增加,但炭疽疫苗与部署对美国军人健康结果的关系仍需进一步研究。